Cargando…

Azathioprine Hypersensitivity Syndrome during Treatment of Severe Interstitial Lung Disease with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Azathioprine is used to treat anti-neutrophil cytoplasmic antibody- (ANCA-) associated vasculitis. Azathioprine hypersensitivity syndrome is often missed. An 81-year-old man undergoing treatment for interstitial pneumonia developed a high fever and was diagnosed with ANCA-associated vasculitis based...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Eri, Asakawa, Tomohiko, Asou, Mea, Nohara, Eri, Seki, Tomoyuki, Araki, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355349/
https://www.ncbi.nlm.nih.gov/pubmed/32695547
http://dx.doi.org/10.1155/2020/8852441
_version_ 1783558258252840960
author Nakano, Eri
Asakawa, Tomohiko
Asou, Mea
Nohara, Eri
Seki, Tomoyuki
Araki, Makoto
author_facet Nakano, Eri
Asakawa, Tomohiko
Asou, Mea
Nohara, Eri
Seki, Tomoyuki
Araki, Makoto
author_sort Nakano, Eri
collection PubMed
description Azathioprine is used to treat anti-neutrophil cytoplasmic antibody- (ANCA-) associated vasculitis. Azathioprine hypersensitivity syndrome is often missed. An 81-year-old man undergoing treatment for interstitial pneumonia developed a high fever and was diagnosed with ANCA-associated vasculitis based on an elevated myeloperoxidase- (MPO-) ANCA titer and renal biopsy findings. After induction therapy, his clinical symptoms improved, but his MPO-ANCA remained elevated (>300 U·L(−1)) and hematuria persisted. Prednisolone plus azathioprine was administered as maintenance therapy. Three exacerbations of the inflammatory response occurred during the subsequent 3 months. In each instance, we suspected opportunistic infection or a flare-up of vasculitis. The first exacerbation was treated with an increased prednisolone dose and antibiotics. At the onset of the second exacerbation, which was accompanied by systemic erythema, we stopped azathioprine and administered antibiotics. The third exacerbation, which occurred the day after restarting azathioprine, involved a fever with chills and an acute inflammatory reaction; we therefore suspected an azathioprine allergy. A drug provocation test was performed, and a hyperinflammatory response was observed. The patient received prednisolone (15 mg·day(−1)) monotherapy; no further fever was observed during the subsequent 2 months. We therefore diagnosed azathioprine hypersensitivity syndrome. Under treatment with prednisolone (5 mg·day(−1)) and mycophenolate mofetil (1 g·day(−1)) (replacing the azathioprine), no signs of relapse or infection have occurred for more than two years. Renal function and the pulmonary lesions are stable, although the high MPO-ANCA titer and hematuria persist. The diagnosis of azathioprine hypersensitivity is often delayed because of the difficulty in identifying the relationship between immunosuppressive agents and hypersensitivity and in distinguishing this from infection or relapse of the primary disease. The misdiagnosis of azathioprine hypersensitivity leads to unnecessary treatment; thus, clinicians should consider allergic reactions specific to azathioprine when switching from induction to maintenance therapy.
format Online
Article
Text
id pubmed-7355349
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-73553492020-07-20 Azathioprine Hypersensitivity Syndrome during Treatment of Severe Interstitial Lung Disease with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Nakano, Eri Asakawa, Tomohiko Asou, Mea Nohara, Eri Seki, Tomoyuki Araki, Makoto Case Rep Pulmonol Case Report Azathioprine is used to treat anti-neutrophil cytoplasmic antibody- (ANCA-) associated vasculitis. Azathioprine hypersensitivity syndrome is often missed. An 81-year-old man undergoing treatment for interstitial pneumonia developed a high fever and was diagnosed with ANCA-associated vasculitis based on an elevated myeloperoxidase- (MPO-) ANCA titer and renal biopsy findings. After induction therapy, his clinical symptoms improved, but his MPO-ANCA remained elevated (>300 U·L(−1)) and hematuria persisted. Prednisolone plus azathioprine was administered as maintenance therapy. Three exacerbations of the inflammatory response occurred during the subsequent 3 months. In each instance, we suspected opportunistic infection or a flare-up of vasculitis. The first exacerbation was treated with an increased prednisolone dose and antibiotics. At the onset of the second exacerbation, which was accompanied by systemic erythema, we stopped azathioprine and administered antibiotics. The third exacerbation, which occurred the day after restarting azathioprine, involved a fever with chills and an acute inflammatory reaction; we therefore suspected an azathioprine allergy. A drug provocation test was performed, and a hyperinflammatory response was observed. The patient received prednisolone (15 mg·day(−1)) monotherapy; no further fever was observed during the subsequent 2 months. We therefore diagnosed azathioprine hypersensitivity syndrome. Under treatment with prednisolone (5 mg·day(−1)) and mycophenolate mofetil (1 g·day(−1)) (replacing the azathioprine), no signs of relapse or infection have occurred for more than two years. Renal function and the pulmonary lesions are stable, although the high MPO-ANCA titer and hematuria persist. The diagnosis of azathioprine hypersensitivity is often delayed because of the difficulty in identifying the relationship between immunosuppressive agents and hypersensitivity and in distinguishing this from infection or relapse of the primary disease. The misdiagnosis of azathioprine hypersensitivity leads to unnecessary treatment; thus, clinicians should consider allergic reactions specific to azathioprine when switching from induction to maintenance therapy. Hindawi 2020-07-03 /pmc/articles/PMC7355349/ /pubmed/32695547 http://dx.doi.org/10.1155/2020/8852441 Text en Copyright © 2020 Eri Nakano et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Nakano, Eri
Asakawa, Tomohiko
Asou, Mea
Nohara, Eri
Seki, Tomoyuki
Araki, Makoto
Azathioprine Hypersensitivity Syndrome during Treatment of Severe Interstitial Lung Disease with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
title Azathioprine Hypersensitivity Syndrome during Treatment of Severe Interstitial Lung Disease with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
title_full Azathioprine Hypersensitivity Syndrome during Treatment of Severe Interstitial Lung Disease with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
title_fullStr Azathioprine Hypersensitivity Syndrome during Treatment of Severe Interstitial Lung Disease with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
title_full_unstemmed Azathioprine Hypersensitivity Syndrome during Treatment of Severe Interstitial Lung Disease with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
title_short Azathioprine Hypersensitivity Syndrome during Treatment of Severe Interstitial Lung Disease with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
title_sort azathioprine hypersensitivity syndrome during treatment of severe interstitial lung disease with anti-neutrophil cytoplasmic antibody-associated vasculitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355349/
https://www.ncbi.nlm.nih.gov/pubmed/32695547
http://dx.doi.org/10.1155/2020/8852441
work_keys_str_mv AT nakanoeri azathioprinehypersensitivitysyndromeduringtreatmentofsevereinterstitiallungdiseasewithantineutrophilcytoplasmicantibodyassociatedvasculitis
AT asakawatomohiko azathioprinehypersensitivitysyndromeduringtreatmentofsevereinterstitiallungdiseasewithantineutrophilcytoplasmicantibodyassociatedvasculitis
AT asoumea azathioprinehypersensitivitysyndromeduringtreatmentofsevereinterstitiallungdiseasewithantineutrophilcytoplasmicantibodyassociatedvasculitis
AT noharaeri azathioprinehypersensitivitysyndromeduringtreatmentofsevereinterstitiallungdiseasewithantineutrophilcytoplasmicantibodyassociatedvasculitis
AT sekitomoyuki azathioprinehypersensitivitysyndromeduringtreatmentofsevereinterstitiallungdiseasewithantineutrophilcytoplasmicantibodyassociatedvasculitis
AT arakimakoto azathioprinehypersensitivitysyndromeduringtreatmentofsevereinterstitiallungdiseasewithantineutrophilcytoplasmicantibodyassociatedvasculitis